BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Johnson (NYSE:JNJ) Odefsey emtricitabine/rilpivirine/tenofovir alafenamide $329.0 $781.0 $1,041.3 217% Genzyme Corp. / Sanofi (Euronext:SAN; NYSE:SNY) Renagel...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

...Actelion Ltd. (SIX:ATLN) Tracleer bosentan $1,209.9 $814.9 $1,086.6 -10% Genzyme Corp. / Sanofi (Euronext:SAN; NYSE:SNY) Renagel...
BioCentury | Jan 11, 2016
Finance

Sowing season

Stephen Hansen, Associate Editor BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year. This...
BioCentury | Jan 13, 2014
Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for...
BioCentury | Apr 15, 2013
Clinical News

RenaGel phosphate binder data

...GELX announced positive results of a second Phase III trial of RenaGel to control elevated serum...
...controls. While RenaGel and PhosLo were comparable in decreasing serum phosphorus and parathyroid hormone levels, RenaGel...
...RenaGel patients had hypercalcemic incidents. GELX has completed enrollment of a Phase II trial of RenaGel...
BioCentury | Apr 15, 2013
Clinical News

RenaGel phosphate binder data

...aluminum-based phosphate binders. After a two-week washout period, patients were given 2, 3 or 4 RenaGel...
...plans an NDA submission in the fourth quarter. GelTex Pharmaceuticals Inc. (GELX), Waltham, Mass. Product: RenaGel...
BioCentury | Apr 1, 2013
Finance

2Q13 Financial Markets Preview: Manning the middle

...cost of goods for Zerenex is much lower than what it costs Sanofi to make Renagel...
BioCentury | Jan 7, 2013
Finance

Buyside View XXI: Sunny side up

...14% Gilead Sciences Inc. (NASDAQ:GILD) Viread tenofovir $737.9 $622.0 $829.3 12% Genzyme Corp./Sanofi (Euronext:SAN; NYSE:SNY) Renagel/Renvela...
BioCentury | Apr 30, 2012
Finance

Highlights of weekly biotech stock moves

...Biopharmaceuticals Inc. (NASDAQ:KERX) jumped $0.39 (29%) to $1.75 on Monday after Zerenex was non-inferior to sevelamer hydrochloride...
BioCentury | Apr 30, 2012
Clinical News

Zerenex ferric citrate: Phase III data

...GBA4-1 trial in ESRD patients on hemodialysis with hyperphosphatemia showed that Zerenex was non-inferior to sevelamer hydrochloride...
...Oct. 7, 2007). Genzyme Inc., a unit of Sanofi (Euronext:SAN; NYSE:SNY, Paris, France), markets Renagel sevelamer hydrochloride...
Items per page:
1 - 10 of 284